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 Tauopathy, which results from the oligomerization of misfolded tau protein in 
neurons, is a feature present in a number of neurodegenerative diseases and a hallmark of 
Alzheimer’s Disease (AD). Tau is an important phosphoprotein that regulates the assembly of 
microtubules, but tauopathy can occur when tau becomes hyperphosphorylated. Phosphorylation 
prevents tau from binding to tubulin, which results in cytosolic accumulation of tau and eventual 
oligomerization. This abnormal accumulation of tau leads to the spreading of 
hyperphosphorylated tau to downstream synaptically connected neurons through an unknown 
mechanism. In AD, the hippocampus is one of the first brain structures to be affected by 
tauopathy in humans. According to previous research, tauopathy occurs primarily between 
principal cells in the hippocampus. The involvement of local inhibitory interneurons in tauopathy 
and their potential role in AD is more controversial. Previous research suggests that tau 
pathogenesis primarily affects principal cells; however, given the importance, diversity, and 
function of interneurons in the hippocampus, it is important to gain a better understanding of the 
interneuron subtypes that may be impacted by the spread of trans-synaptic tau into the 
hippocampus. Understanding the involvement of interneurons in trans-synaptic tau transmission 
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is important to understanding neurodegeneration in AD and other neurodegenerative disorders. 
To investigate this, both male and female genetically-modified mice underwent surgery to 
examine the trans-synaptic spread of pathogenic tau (EGFP-Tau P301L) from the entorhinal 
cortex to hippocampal neurons. Histology and imaging analysis of brain sections were performed 
to examine the hippocampal cells impacted by trans-synaptic spread of tau. Results show that 
pathogenic tau can trans-synaptically spread from presynaptic neurons in the entorhinal cortex 
into downstream hippocampal interneurons and also that hippocampal interneurons are capable 
of trans-synaptically spreading tau. Future studies examining the specific subtypes of 
hippocampal interneurons vulnerable to trans-synaptic spread of tau will be important for a better 
understanding of disease progression, which could lead to uncovering new therapeutic targets for 















In just half a century, the life expectancy of the world has increased significantly. 
According to the data collected by The World Bank, an individual’s average life expectancy rose 
from 53 years old in 1960 to 72 in 2016 (Life expectancy, 2019). Globally, people are getting 
older; however, with increased longevity comes an increase in the probability of developing age-
related diseases such as Alzheimer’s disease (AD). In the United States alone, 5.3 million 
individuals have been diagnosed with AD with 5.1 million of these individuals being 65 years 
old or older. Thus, this is a disease predominantly affecting older individuals, and in a few years 
its prevalence is expected to significantly rise (Alzheimer’s Association, 2015). 
AD is characterized as a neurodegenerative disorder in which the progression of the 
disease results in memory loss and cognitive impairment (Khyade, Khyade, & Jagtap, 2016; 
Wilson et al., 2012). Dementia has been defined by Folstein and McHugh as “the clinical 
syndrome of mental life characterized by substantial global decline in cognitive function that is 
not attributable to alteration in consciousness” (Breitner, 2006). The degree of dementia 
increases as an individual goes through four stages: pre-dementia, early (mild), moderate, and 
advanced (severe) (Khyade, Khyade, & Jagtap, 2016). Pre-dementia and the early stage of AD 
are characterized by impaired learning and memory; however, individuals are still capable of 
living independently in these stages (Storandt & Hill, 1989). In these early stages, verbal 
memory is typically the first aspect of memory that is affected (Linn et al., 1995). In moderate 
and severe stages of AD, individuals are unable to live independently and memory/cognition are 
severely impaired compared to the predementia and early stages of AD (Khyade et al., 2016). 
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Furthermore, in these later stages, individuals have a three year life expectancy (Wimo, Winblad, 
Stoffler, Wirth, & Mobius, 2003).  
As the sixth leading cause of death in the United States (“2015 Alzheimer’s disease facts 
and figures,” 2015), the impact of AD has motivated researchers to investigate the pathological 
basis of the disease. There are three popular hypothesis to explain the cause of AD: the genetic or 
amyloid cascade hypothesis, the cholinergic hypothesis, and the tau hypothesis (Khyade et al., 
2016). The genetic or amyloid hypothesis posits that a number of genetic mutations occur in the 
amyloid precursor protein (APP) or in catalytic enzymes involved in processing APP (presenilin 
1 and 2) (Price, Tanzi, Borchelt, & Sisodia, 1998). It is believed that in the amyloid cascade 
hypothesis, the amyloid precursor protein is cleaved in the endosomal-lysosomal pathway to 
form amyloid beta, which is then released into the extracellular space resulting in amyloid beta 
plaque formation (O’Brien & Wong, 2011) Accumulation of amyloid beta plaques can 
eventually result in neurofibrillary tangles evident in later stages of AD (Hardy & Higgins, 1992; 
Maccioni, Farías, Morales, & Navarrete, 2010). However, the role of amyloid beta in the disease 
state remains unclear because research has shown that amyloid beta plaques can exist in a normal 
cognitive brain (Morris, Clark, & Vissel, 2014). In contrast, no confirmed genetic mutations have 
been causally correlated to the far more prevalent late-onset form of AD. However, previous 
research suggest that expression of the APOE4 isoform of apolipoprotein E has a weak 
correlation to an individual acquiring late-onset sporadic AD; and, in contrast, the APOE2 
isoform appears to have protective effects against AD (Strittmatter & Roses, 1996). The 
cholinergic hypothesis posits that cholinergic neurons, which are important for learning and 
memory, are some of the first neuronal subtypes to be impacted at the onset of AD (P. T Francis, 
Palmer, Snape, & Wilcock, 1999; Terry, 2003). This hypothesis provides a useful 
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pharmaceutical strategy (combatting the loss of cholinergic neurons) that has worked well for 
early stages of AD; however, its efficacy diminishes as AD progresses to later stages (Bartus, 
2000). The most popular hypothesis amongst the three, the tau hypothesis, suggests that tau 
hyperphosphorylation and aggregation is the key factor for AD (Maccioni et al., 2010). Tau 
hyperphosphorylation, spread, and aggregation is also known as tauopathy, and many researchers 
are in agreement that this is likely an important underlying cause of AD (Fernández, Rojo, 
Kuljis, & Maccioni, 2008; Kosik, Joachim, & Selkoe, 1986; Maccioni, Rojo, Fernández, & 
Kuljis, 2009; Rojo et al., 2008).  
 
Tauopathy 
Tauopathy is a feature present in a number of neurodegenerative diseases associated with 
dementia and cognitive decline. It is a hallmark of AD (Rojo et al., 2008), but several other 
diseases also display tau-dependent neurofibrillary tangles such as Argyrophilic grain disease 
(Tolnay & Clavaguera, 2004), supranuclear palsy, corticobasal degeneration, Pick’s Disease, 
frontotemporal dementia, (Wattez & Delacourte, 1999; Spillantini, Van Swieten, & Goedert, 
2000) and Parkinson’s Disease (Lei et al., 2010), all of which are associated with increased 
dementia and cognitive decline. The involvement of tau in many neurogenerative diseases should 
come as no surprise given the important function tau has in the central nervous system.  
Tau is an important phosphoprotein that regulates the assembly of microtubules 
(Weingarten et al., 1975). In human, the coding sequence for the microtubule associated protein 
tau (MAPT) gene is located on chromosome 17 and is alternatively spliced to produce 6 isoforms 
(Goedert, Wischik, Crowther, Walker, & Klug, 1988). Studies indicate that tau, although also 
located in the peripheral nervous system, is predominantly located in axons of neurons of the 
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central nervous system (Shin et al., 1991), supporting the observation that tau is particularly 
important in microtubule organization of axons (Harada et al., 1994). Tau is able to regulate 
microtubules by being phosphorylated by a protein kinase, PKN (Taniguchi et al., 2001); 
however, it can also be phosphorylated and dephosphorylated by a range of proteins (Billingsley 
& Kincaid, 1997).  
Tauopathy occurs at least in part because tau becomes hyperphosphorylated. 
Phosphorylation of specific residues prevents tau from binding to tubulin, which results in 
cytosolic accumulation of tau and eventual oligomerization (Lindwall & Cole, 1984). This 
abnormal accumulation of tau leads to the trans-synaptic spread of hyperphosphorylated tau by 
an unknown mechanism (Rojo et al., 2008). This abnormal phosphorylation is a serious concern 
not only because of aggregation and trans-synaptic spread, but because destabilized microtubules 
in neurons (axons predominantly) results in a compromised axonal transport system, which can 
ultimately lead to cell death (Kosik et al., 1986). This cell death helped early scientists identify 
which brain regions are first affected by tauopathy as cell death appears to occur in a serial 
fashion.   
 
The Entorhinal Cortex, Hippocampus, and Tauopathy 
In AD, the first brain structure in humans to be affected by tauopathy is the entorhinal 
cortex (Braak & Del Tredici, 2012; Gómez-Isla et al., 1996; Khan et al., 2014; Moreno et al., 
2007; Whitwell et al., 2007), more specifically the transentorhinal cortex (Braak & Braak, 1995). 
The entorhinal cortex is located in the medial temporal lobe and functions as the “gate-keeper” 
between the neocortex and the hippocampus. The entorhinal cortex is usually separated into two 
regions: the medial entorhinal cortex and the lateral entorhinal cortex. Both lie next to each other 
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and encode different modalities. The medial entorhinal cortex is primarily involved in spatial 
memory (Tsao et al., 2018). This is supported by studies that have shown a correlation between 
spatial memory diminishing and the volume of the medial entorhinal cortex decreasing (Fox et 
al., 1996; Frisoni et al., 1999). The lateral entorhinal cortex is primarily involved in novel object- 
context recognition (Wilson et al., 2013). Layer II and layer III in both the medial and lateral 
entorhinal cortex each project to different region and areas in the hippocampus. Layer II of the 
medial entorhinal cortex projects to the middle third portion of the molecular layer in the DG 
region of the hippocampus and to the deep portion of the stratum lacunosum-moleculare layer in 
the CA3 region of the hippocampus. Layer II of the lateral entorhinal cortex projects to the outer 
third portion of the molecular layer in the DG region of the hippocampus and the most 
superficial portion of the stratum lacunosum in the CA3 region of the hippocampus. Layer III of 
the medial entorhinal cortex projects to the CA1 stratum lacunosum adjacent to CA3 region of 
the hippocampus. Layer III of the lateral entorhinal cortex projects to CA1 stratum lacunosum 
adjacent to the subiculum region of the hippocampus (Canto & Witter, 2012a, 2012b). See 
Figure 1 and Figure 2 for connections from the entorhinal cortex.    
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Figure 2: Skutella, T., & Nitsch, R. (2001). New molecules for hippocampal development. 
Trends in neurosciences, 24(2), 107-113. 




 The hippocampus is the next brain structure to be affected by tauopathy (Fox et al., 1996; 
Frisoni et al., 1999). The hippocampus is located in the medial temporal lobe and has been 
shown to be primarily involved in learning and memory (Erickson et al., 2011; L. R. Squire, 
1986; Larry R. Squire, 1992; Winocur, Wojtowicz, Sekeres, Snyder, & Wang, 2006). Typically, 
the hippocampus is divided into four regions: dentate gyrus, CA3 region, CA1 region and 




Figure 3: Torrealba, F., & Valdés, J. L. (2008). The parietal association cortex of the rat. 
Biological research, 41(4), 369-377. 
 
According to previous research, the neurons affected by pathogenic tau and trans-
synaptic spread in the entorhinal cortex and hippocampus are thought to be principal 
glutamatergic neurons (Steward & Scoville, 1976; Varga, Lee, & Soltesz, 2010). This finding is 
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further supported by research showing that tau trans-synaptically spreads between the principal 
cells of each brain structure (Paul T. Francis, 2003; Palop & Mucke, 2010). These findings 
suggest that principal cells are exclusively involved in tauopathy; however, concerns arise with 
this reasoning because principal cells are not the only cell types residing in the hippocampus and 
because there is evidence that interneurons may be involved in tauopathy (Koliatsos et al., 2006; 
Loreth et al., 2012; Levenga et al., 2013). 
 
Interneurons and Tauopathy 
In addition to principal cells, inhibitory interneurons are another group of cells found in 
the hippocampus. Inhibitory interneurons are crucial to the gating of inputs to the hippocampus, 
the integration of excitatory inputs within the dendritic trees of principal cells, and the generation 
of behaviorally relevant rhythms observed in principal cells of the hippocampus (Freund & 
Buzsáki, 1998).  Dysfunction in interneurons has also been linked to disrupt cognitive function 
as well as play a role in the generation of seizures (Buzsáki, 2002; Chauviere et al., 2009). The 
scientific community continues to investigate hippocampal interneurons and the expanding list of 
their subpopulations, but we remain in the midst of discovering more inhibitory interneuron 
subpopulations that vary in morphology, function, and connectivity. Given the wide range of 
roles and functions of interneurons in the hippocampus, investigating how interneurons are 
involved in tauopathy could be essential for understanding mechanisms contributing to cognitive 
dysfunction in neurodegenerative diseases like AD.  
The relationship between interneurons and tauopathy and their potential role in AD 
remains contentious. Previous research suggests that interneurons are not actively involved in 
trans-synaptic tau transmission (Paul T. Francis, 2003; Verret et al., 2012). Others suggest that 
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interneurons have no role in AD (Fu et al., 2019). However, given the diversity and function of 
interneuron subtypes, their importance in regulating hippocampal network function, and studies 
that suggest that certain interneuron subtypes may be impacted by pathogenic tau, further 
investigation into their role in tauopathy and AD is warranted.  
 
Theory 
This study aims to identify and classify interneurons and their subtypes impacted by the 
trans-synaptic spread of tau. If interneurons are affected, determining what interneuron subtypes 
are affected, which hippocampal subregions are being affected, and comparing the relative 
number of interneurons to principal neurons being affected is essential to understanding 
tauopathy. By providing these answers to our gap in knowledge regarding trans-synaptic spread 
of tau in the hippocampus may provide important information necessary for discovering new 
therapeutic targets for neurodegenerative disease like AD.  
 
Materials and Methods 
Animals 
Both adult male and female genetically-modified mice were used to examine the trans-
synaptic spread of pathogenic tau (EGFP-Tau P301L) from the entorhinal cortex to hippocampal 
neurons. To determine the hippocampal cell types vulnerable to the spread of  EGFP-Tau P301L 
we used the following Cre-recombinase driver mouse lines: Viptm1(cre)Zjh /J (JAX Stock No. 
010908), B6;129P2-Pvalbtm1(cre)Arbr /J (JAX Stock No. 008069), Slc32a1 tm2(cre)Lowl/J (JAX 
Stock No. 016962), Cr-IRES-Cre (JAX Stock No. 010774), and C57BL/6-Tg(Pvalb-
tdTomato)15Gfng/J (Jax Stock No. 027395)  (See Table 1 for purpose of each animal ). The Cre-
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driver lines were crossed to a Cre-dependent tdTomato reporter line Ai14 (B6.Cg-
GT(ROSA)26Sortm14(CAG-tdTomato)Hze/J)  (JAX Stock No. 007914 ) to identify VGAT 
positive GABAergic interneurons (cells were classified as principal cells based off of 
morphology and whether it was VGAT- tdTomato negative). These animals were then crossed 
with animals that underwent surgery to selectively infect MEC or ECIII cells using a flex virus 
(an AAV1-hSYN1-DIO-GFPtauP301L-WPRE injected in to selectively express pathogenic tau 
in Cre-containing principal cells of layer III of the medial entorhinal cortex) that is under the 
control of the human synapsin promotor or tTA virus (an AAV1-TRE-GFPtauP301L-WPRE to 
selectively express pathogenic tau in tTA-containing principal cells of layer II of the medial 
entorhinal cortex) that is under the control of the tetracycline response element. The specifics of 
the rationale are explained later in this section. All animals were housed in an animal care 
facility approved by the American Association for the Accreditation of Laboratory Animal Care. 
Animal experimental procedures followed a protocol approved by the Institutional Animal Care 
and Use Committee of Virginia Commonwealth University (AD20205). This protocol adheres to 
the ethical guidelines described in the Guide for the Care and Use of Laboratory Safety Animals 





List of all animal strains and the purpose of each animal used in this experiment.  
 
   
 13 
Surgery 
All instruments were sterilized and an aseptic field was created before surgery. All 
animals were initially anesthetized with a mixture of ketamine (100 mg/kg) and xylazine (2.5--5 
mg/kg) via intraperitoneal (IP) injection. Atropine was administered to control secretions (0.04 
mg/kg) via subcutaneous injection (SC). After animals were placed on the robot stereotaxic 
(Neurostar, Tubingen, Germany), the site of incision was wiped with Betadine (Purdue Products 
L.P. Stanford, CT 06901-3431) alternated with 70% ethanol three times. During the procedure, 
anesthesia was maintained with O2 supplemented with 1.0% isoflurane. An incision was made 
along the skull, the skin was pulled back, and a very small hole was drilled over the area of 
interest (the entorhinal cortex or the hippocampus). An aluminosilicate glass pipette containing 
an adeno-associated virus (AAV) that expressed eGFP-Tau P301L under the control of the 
tetracylcine response element (AAV1-TRE-eGFPtau) or the human synapsin promoter (AAV1-
hSYN1-DIO-GFPtauP301L) was injected into the medial entorhinal cortex (MEC) using a 
Hamilton syringe (Hamilton 87930, Franklin, MA) at a rate of 100 nl/min using a motorized 
nanoinjector (Neurostar). As a reminder, the animals injected were either a B6.Cg-Tg(Klk8-
tTA)SMmay/MullMmmh (Stock # 031779-MU) strain (Mutant Mouse Resourse and Research 
Center), which is a NOP-tTA animal that allows for specific tTA expression in the layer II 
medial entorhinal cortex, or an ECIII (a gift from S. Tonegwa, MIT), which is a pOXR1-Cre 
animal that expresses Cre in MEC layer III of the entorhinal cortex. These mice strains were 
chosen based off successful previous experiments in our lab and other labs investigating tran-
synaptic tau transmission in the hippocampus. After surgery was complete, animals were 
monitored daily for dehydration, lethargy, weight loss and signs of inflammation for minimum of 
3 days.  
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Tissue Processing for Immunohistochemistry  
At specific time points following viral injection (3 -6 months), each animal was deeply 
anesthetized with a combination of 200 mg/kg ketamine, 20 mg/kg xylazine IP for tissue 
recovery and immunofluorescence processing. These post injection time points were chosen 
because this is the earliest time point that we observed trans-synaptic spreading of tau. Once 
animals no longer responded to toe pinch, animals were transcardially perfused with ice cold 
carbogen-bubbled artificial cerebrospinal fluid (aCSF which contains 125 mM of NaCl, 3.0 mM 
of KCl, 1.2 mM of CaCl, 1.2 mM of MgSO4.7H2O, 1.25 mM of NaH2PO4.H2O, 25 mM of 
NaHCO3, and 25 mM of glucose) followed by  4% paraformaldehyde (PFA) in phosphate 
buffered saline (PBS, Boston BioProducts, Cat # BM-155, pH 7.4 +/- 2). The aCSF was perfused 
at 6 mL/min and the 4% PFA was perfused at 2 mL/min using a Peri-Star Pro Pump (Sarasota, 
Florida), brains were stored in PFA at 4 degrees for at least 48 hours. 
Microscopy was performed at the VCU- Department of Anatomy & Neurobiology 
Microscopy Facility, supported in part, with funding from the NIH-NCI Cancer Center Support 
Grant P30 CA0116059. Brains were washed in PBS (Quality Biological, Cat. # 119-069-101, 
Gaithersburg, Maryland). Brains were then transferred to 30% sterile-filtered sucrose for a few 
days until brains saturated, indicated by falling to the bottom of the scintillation vial. Brains were 
blocked using a mouse brain matrix and then the blocked brains were embedded in Tissue Tek 
O.C.T (Electron Microscopy Sciences, Cat # 62550-01) using a Tissue-Tek Cryomold (Sakura, 
Torrance, California). Brains were then hardened using wet ice for 15 minutes followed by dry 
ice until O.C.T. was opaque. Once another member of the laboratory had completed the 
preceding steps, I performed the following procedures. The tissue was then sectioned using 
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ThermoScientific cryostat (Waltham, Massachusetts) at a slice thickness of 20 microns. Cut 
brain sections were placed in PBS using a small bristle artist paint brush.  
After brain sections were collected, wide field fluorescence microscopy was used to 
determine which brain sections had the brightest trans-synaptic eGFP-Tau P301L expression. 
Once identified, 15 brain sections encompassing the brightest expression of GFP within the 
hippocampus were taken in serial order. Antibodies directed toward cell type specific markers 
were used to identify which cell types contained  trans-synaptic eGFP-Tau P301L. Primary and 
secondary antibodies (See Table #2) were then added per normal protocol using free-floating 
brain sections in appropriate blocking buffer. All antibody incubations other than washes were 
done at 4 degrees. All washes were done in PBS. Brain sections were mounted on Fisherbrand 
colorfrost slides (ThermoScientific, Waltham, Massachusetts) using ProLong Gold antifade 





Primary and Secondary Antibody List used for this experiment 
 
 
Quantitative and Qualitative Analysis 
All brain sections were stored overnight at room temperature after mounting. Each brain 
sections was then examined with the BX53 Upright Microscope (Olympus). During each 
examination, the following cell counts were collected by visualization with the OLYMPUS 
cellSens dimension software (Olympus): the total number of cells containing trans-synaptic 
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pathogenic tau in all sections that successfully underwent antibody incubation, the relative 
number of principal cells and inhibitory interneurons located in the dentate gyrus, CA3 and CA1 
subregions of the hippocampus, in addition to the relative number of interneurons affected in 
each layer of each region of the hippocampus. A total number of 6 transgenic mice were used in 
this experiment and a total number of 1,131 cells containing trans-synaptic pathogenic tau were 
counted. After examination, brain sections were stored in a -20°C freezer. Brain sections that 




For all experiments, we set out to determine the hippocampal neuronal subtypes in the 
hippocampus that were vulnerable to the trans-synaptic spread of tau. How this was 
accomplished for each group is described below. For all experiments, all interneurons described 
are VGAT positive and fluoresced tdTomato. All other cells were classified as principal cells 
once morphology was confirmed. (See Table #3 for the Animal Information and the Counts for 








Animal Information and the Counts for the Total Number of Cells Containing Trans-Synaptic Pathogenic 
Tau in this Experiment. Table can also be viewed in the appendix section.  
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MEC Injections 
 In this group, we found that inhibitory interneurons accumulated trans-synaptic spread of 
pathogenic tau (Fig. 4 and Fig. 6). In fact, accumulation of trans-synaptic spread of tau was more 
prevalent in inhibitory interneurons than principal cells, which is contrary to previous research 
concerning the involvement of interneurons in trans-synaptic spreading of tau.  
We first examined trans-synaptic spread from Layer II MEC neurons into downstream 
hippocampal neurons. We did this by injecting an AAV that expresses GFPtau under the control 
of a TRE promoter in MEC-tTA driver mice. The MEC-tTA mouse line primarily expresses tTA 
in MEC LII projection neurons; however, a smaller cohort of neurons also express tTA in MEC 
LIII. All neurons that received trans-synaptic pathogenic tau by transfecting LII MEC neurons 
were taken into account when determining the following proportions.  
The proportions that follow are out of the total number of cells that contain trans-synaptic 
pathogenic tau in the DG, CA3, and CA1 region of the hippocampus. Cells were classified as 
GABAergic (interneuron) or non-GABAergic (principal cells) based on the expression of 
tdTomato in GABAergic neurons (VGAT-Cre x ai14 tdTomato reporter). When examining the 
DG region, 26% of interneurons contained tau, as opposed to 1% of principal cells (Fig. 5A). 
When examining the CA3 region, 8% of interneurons contained tau, as opposed to 1% of 
principal cells that contained tau (Fig. 5A). When examining the CA1 region, 6% of interneurons 
contained tau, as opposed to 58% of principal cells that contained tau (Fig. 5A).  
We next examined the proportions of all the neurons that received trans-synaptic GFPtau 
in the DG, CA3, and CA1 subregions of the hippocampus. Cells were classified as GABAergic 
(interneuron) or non-GABAergic (principal cells) based on the expression of tdTomato in 
GABAergic neurons (VGAT-Cre x ai14 tdTomato reporter). The proportions that follow are 
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from the total number of cells that contained trans-synaptic pathogenic tau in the DG, CA3, and 
CA1 region of the hippocampus respectively. Of all neurons in the DG region that trans-
synaptically expressed GFPtau, 13% were interneurons located in the molecular layer, 27% were 
interneurons and 2% were principal cells located in the granule cell layer, 54% were interneurons 
and 4% principal cells (presumptive mossy cells) located in the dentate hilus (Fig. 5B). 
Surprisingly, 94% neurons that contained trans-synaptic pathogenic tau in the DG region were 
interneurons, which is in contrast to current hypotheses.  
Of all neurons in the CA3 region that trans-synaptically expressed GFPtau, 3% were 
interneurons and 5% were principal cells located in the stratum oriens, 29% were interneurons 
and 3% were principal cells located in the stratum pyramidale, 24% were interneurons and 3% 
were principal cells located in the stratum radiatum, and 31% were interneurons and 3% were 
principal cells located in the stratum lacunosum-moleculare (Fig. 5C). Surprisingly, 87% of 
neurons that contained trans-synaptic pathogenic tau in the CA3 region were interneurons, which 
is in contrast to the current hypotheses.  
Of all neurons in the CA1 region that trans-synaptically expressed GFPtau, 2% were 
interneurons and 82% were principal cells located in the stratum oriens, 3% were interneurons 
and 7% were principal cells located in the stratum pyramidale, 2% were interneurons and 11% 
were principal cells located in the stratum radiatum, and 2% were interneurons and 0% were 
principal cells located in the stratum laconosum (Fig. 5D).  
Because eGFPTau-P301L was found to trans-synaptically spread into a significant 
number of GABAergic interneurons, we next attempted to determine whether specific subtypes 
of interneurons were more vulnerable to eGFPTau-P301L infection. Calretinin, a calcium-
binding protein, is expressed in a small distinct subset of GABAergic interneurons that 
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exclusively innervate other interneurons but not principal cells. Modification of calretinin 
interneuron function by pathogenic tau could therefore have profound impact on the activity of 
the entire population of hippocampal interneurons. Thus, we used immunofluorescence to 
determine whether calretinin interneurons were susceptible to the trans-synaptic spread of 
eGFPTau-P301L. We detected no spread of eGFPTau-P301L into calretinin neurons in the 
molecular or granule cell layer. However, in the hilus of DG, 5% of eGFPTau-P301L expressing 
neurons also stained positive for calretinin (Fig. 7). In CA3, all eGFPTau-P301L positive 
neurons were negative for calretinin in the stratum oriens and the stratum radiatum. However, 
7% of neurons in the stratum pyramidale and 7% in the stratum lacunosum-moleculare were 
positive for calretinin interneurons containing trans-synaptic pathogenic tau (Fig.  7). 
Interestingly, eGFPTau-P301L did not appear to trans-synaptically spread into CA3 principal 
cells in these studies. In CA1, of all the eGFPTau-P301L expressing neurons only 1% of stained 
positive for calretinin in the stratum oriens and stratum pyramidale and an additional 6% stained 
positive for calretinin in the stratum radiatum. None of the eGFPTau-P301L positive neurons in 
the stratum lacunosum-moleculare were also positive for calretinin (Fig. 7). Therefore, although 
calretinin neurons only make up a very small percentage of neurons that received the trans-










Figure 4: Medial Entorhinal Cortex Layer II Injection- Targets DG & CA3 
A: Tau containing cells are labeled. Arrows point to GFP-tau containing cells that overlap 
with VGAT interneurons. 
B: VGAT interneurons are labeled. Arrows point to GFP-tau containing cells that overlap 
with VGAT interneurons. 
C: Arrows point to GFP-tau containing cells that overlap with VGAT interneurons. 
D: Picture of the mouse hippocampus. Arrow points to hippocampal region of interest for 











Figure 5: Percentage of Tau Containing Cells after Layer II MEC Injection 
A, B, C, & D: Proportions of tau containing cells in each region and sub region of the 
hippocampus (P = principal cell; I = interneuron; SM = stratum molecular layer; SG = stratum 
granule cell layer; Hilus; SO = stratum oriens; SP = stratum pyramidale; SR = stratum radiatum; 













Figure 6: Medial Entorhinal Cortex Layer II Injection- Targets DG & CA3 
A: Tau containing cells are labeled. Arrow points to a GFP-tau containing cell. 
B: VGAT interneurons fluorescing tdTomato are labeled. Arrow points to a VGAT 
interneuron. 
C: Calretinin interneurons are labeled. Arrow points to a calretinin interneuron. 
D: Calretinin interneurons are a small subset of VGAT interneurons. Arrow points to a VGAT 
positive and calretinin positive interneuron.  
E: Tau containing cells are labeled. Arrow points to GFP-tau containing cells that overlap with 
calretinin interneuron. 
F: Picture of the mouse hippocampus. Arrow points to hippocampal region of interest for this 












Figure 7: Percentage of Tau Containing Calretinin Positive Cells after Layer II MEC Injection 
Proportions of tau containing cells in each region and sub region of the hippocampus (SM = stratum 
molecular layer; SG = stratum granule cell layer; Hilus; SO = stratum oriens; SP = stratum pyramidale; 




In this group, we found that inhibitory interneurons accumulated trans-synaptic spread of 
pathogenic tau (Fig. 8). In fact, based on proportions, accumulation of trans-synaptic spread of 
tau was more prevalent in inhibitory interneurons than principal cells, which is contrary to 
previous research concerning the involvement of interneurons in trans-synaptic spreading of tau.  
We next examined the trans-synaptic spread of eGFPTau-P301L into postsynaptic 
hippocampal neurons following the virally-mediated transfection of LIII neurons of the MEC. 
Expression of eGFPTau-P301L depended on Cre-mediated recombination, which was largely 
restricted to layer III principal cells in the MEC. Layer III MEC neurons project exclusively to 
the CA1 region of the hippocampus. Therefore, we expected to observe trans-synaptic spread of 
eGFPTau-P301L into CA1 neurons but not those of the DG or CA3.  
The proportions that follow are out of the total number of cells containing trans-synaptic 
pathogenic tau in the CA1 region of the hippocampus. As expected, we observed no expression 
of eGFPTau-P301L in postsynaptic neurons in the DG or CA3 following eGFPTau-P301L 
transfection of LIII MEC projection neurons. When examining the CA1 region, 32% of 
interneurons contained trans-synaptic pathogenic tau, as opposed to 68% of principal cells that 
contained trans-synaptic pathogenic tau (Fig. 9A). This observation is important as interneurons 
as a whole make up less than 20% of the neurons in hippocampal CA1. This suggests that 
subsets of hippocampal CA1 inhibitory interneurons may be particular vulnerable to the trans-
synaptic spread of eGFPTau-P301L. 
We next examined the spread of eGFPTau-P301L into neurons of the different layers of 
CA1. Of all the interneurons expressing eGFPTau-P301L in CA1, 5 % were found in stratum 
oriens, 24% in stratum pyramidale, 3% in stratum radiatum, and none in stratum lacunosum-
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moleculare. For “principal” non-GABAergic neurons, 16% were found in stratum oriens, 48% in 
stratum pyramidale, 3% in stratum radiatum, and 1% in stratum lacunosum-moleculare (Fig. 9B). 
Because inhibitory interneuron subtypes are found to be preferentially found in different layers, 
these findings may guide future studies toward identifying interneuron subtypes that are 


















Figure 8: Medial Entorhinal Cortex Layer III Injection- Targets CA1 
A:  Tau containing cells are labeled. Arrows point to GFP-tau containing cells that overlap 
with VGAT interneurons. 
B: VGAT interneurons are labeled. Arrows point to GFP-tau containing cells that overlap with 
VGAT interneurons. 
C: Arrows point to GFP-tau containing cells that overlap with VGAT interneurons. 
D: Picture of the mouse hippocampus. Arrow points to hippocampal region of interest for this 




Figure 9: Percentage of Tau Containing Cells after Layer III MEC Injection 
A & B: Proportions of tau containing cells in the CA1 region of the hippocampus (P = principal 
cell; I = interneuron; SM = stratum molecular layer; SG = stratum granule cell layer; Hilus; SO = 















vCA1 Injections  
In this group, we found that principal cells accumulated trans-synaptic spread of 
pathogenic tau (Fig. 10). This suggest that inhibitory interneurons are actively involved in trans-
synaptic spread of tau, which is contrary to previous research concerning the involvement of 
interneurons in trans-synaptic spreading of tau.  
Because trans-synaptic tau spreads into a significant proportion of interneurons in 
hippocampal CA1, we asked whether CA1 interneurons can trans-synaptically spread tau to CA1 
pyramidal cells. To do this we expressed eGFPTau-P301L in GABAergic neurons in 
hippocampal CA1 and assessed if eGFPTau-P301L was then passed to postsynaptic CA1 
pyramidal neurons. Please refer to Figure 10 and Figure 11 for these findings. 
Although we targeted hippocampal CA1 for our AAV eGFPTau-P301L injections, our 
injections permitted diffusion of virus into CA3 and DG resulting in expression of eGFPTau-
P301L in all 3 regions of the hippocampus. When examining the hippocampus as a whole, 11% 
of eGFPTau-P301L was found in DG interneurons, 2% in DG principal cells (presumptive 
mossy cells), 11% in CA3 interneurons, 10% in CA3 principal cells, 36% in CA1 interneurons, 
and 30% CA1 principal cells (Fig. 11 A). Therefore, CA1 interneurons were capable of 
transmitting eGFPTau-P301L to postsynaptic CA1 principal cells. However, perhaps more 
interesting was the observation that interneurons in DG and CA3 could also trans-synaptically 
spread eGFPTau-P301L into principal neurons of the DG and CA3, respectively. This latter 
observation was interesting because local interneurons were capable of passing eGFPTau-P301L 
to postsynaptic principal cells in DG and CA3 whereas inputs from the entorhinal cortex 
appeared incapable. Therefore, it appears that vulnerability to trans-synaptic spread of eGFPTau-
P301L is synapse specific and perhaps not cell type specific.  
 30 
We next examined the layer specific expression of eGFPTau-P301L in each region of the 
hippocampus. In the DG, 11% of eGFPTau-P301L neurons were molecular layer interneurons, 
3% were molecular layer principal cells, 30% were granule cell layer interneurons, 5% were 
granule cell layer principal neurons, 45% were hilar interneurons and 5% were hilar principal 
cells (Fig. 11 B). In CA3, 23% of eGFPTau-P301L neurons were in stratum oriens interneurons, 
28% were stratum oriens principal cells, 22% were stratum pyramidale interneurons, 2% were 
stratum pyramidale principal cells, 23% were stratum radiatum interneurons, and 3% in stratum 
radiatum principal cells (Fig. 11 C). No interneurons or principal cells expressing eGFPTau-
P301L were observed in the stratum lacunosum-moleculare of CA3. In CA1, 26% of eGFPTau-
P301L neurons were stratum oriens interneurons, 31% were statum pyramidale principal cells 
15% were stratum pyramidale interneurons, 8% were stratum pyramidale principal 8% were 
interneurons in stratum radiatum, 4% were principal cells in stratum radiatum, 5% were 
interneurons in stratum lacunosum-moleculare and 3% were non GABAergic neurons in stratum 











Figure 10: Ventral CA1 Injection 
A: Tau containing cells are labeled. Arrows point to GFP-tau containing cells that do not overlap with 
VGAT interneurons. 
B: VGAT interneurons are labeled.  
C: Arrows point to GFP-tau containing cells that do not overlap with VGAT interneurons. 












Figure 11: Percentage of Tau Containing Cells after vCA1 Injection 
A, B, C, & D: Proportions of tau containing cells in each region and sub region of the 
hippocampus (P = principal cell; I = interneuron; SM = stratum molecular layer; SG = stratum 
granule cell layer; Hilus; SO = stratum oriens; SP = stratum pyramidale; SR = stratum radiatum; 







To examine the trans-synaptic spread of eGFPTau-P301L, we used an adeno associated 
virus (AAV) strategy in which eGFP-Tau P301L was expressed under the control of the 
tetracylcine response element (AAV1-TRE-eGFPtau) or the human synapsin promoter (AAV1-
hSYN1-DIO-GFPtauP301L) was injected into either layer II of the medial entorhinal cortex 
(MEC group), layer III of the medial entorhinal cortex (ECIII group), or ventral CA1 of the 
hippocampus (VGATtd group). This was done to identify and classify interneurons and their 
subtypes vulnerable to the trans-synaptic spread of tau. Because interneurons were trans-
synaptically labelled with eGFPTau-P301L, we determined the relative susceptibility of 
interneurons to the trans-synaptic spread of tau of interneurons compared to principal neurons 
and we further explored which subpopulations of interneurons contained pathogenic tau based on 
their anatomical location and co-expression of calretinin. In this study, vesicular GABAergic 
transporter (VGAT) interneurons, which is found in all interneurons in the hippocampus, 
expressed tdTomato (Rudy, Fishell, Lee, & Hjerling-Leffler, 2011). So, interneurons were 
classified as containing pathogenic tau if cells were positive for both GFP and tdTomato.  
 
MEC Injections 
The known projection from layer II of the medial entorhinal cortex is to the DG and CA3 
region of the hippocampus. We examined trans-synaptic spread from Layer II MEC neurons into 
downstream hippocampal neurons. We did this by injecting an AAV that expresses GFPtau 
under the control of a TRE promoter in MEC-tTA driver mice. The MEC-tTA mouse line 
expresses tTA in MEC LII projection neurons, so we expected eGFPTau-P301L to progress from 
layer II of the medial entorhinal cortex and only infect cells (principal cells and interneurons) in 
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the DG and CA3 region of the hippocampus. As expected, the DG and CA3 cells of the 
hippocampus were contained pathogenic tau. Based on the proportions, it would appear that 
interneurons in these regions are more susceptible to trans-synaptic spread of tau. This is 
contrary to previous research suggesting that principal cells are predominantly involved in trans-
synaptic spread of tau. It was also determined that at least one subpopulation of interneurons, 
calretinin interneurons, are susceptible to the trans-synaptic spread of tau. GABAergic 
interneurons make up about 10% - 15% of cells in the hippocampus (Pelkey et al., 2017) and 
calretinin (CR+) interneurons make up  a small proportion (~ 10%) of GABAergic interneurons 
(Gulyás, Hájos, & Freund, 1996). Although CR+ interneurons that contain pathogenic tau are 
small in numbers, the fact that this small subset of interneurons contains trans-synaptic 
pathogenic tau is impressive. This finding is also interesting because calretinin interneurons are 
interneuron selective and do not innervate principal cells. So, their effect can be significant 
through their influence in inhibitory interneurons through disinhibition. Future studies should 
determine the other interneurons subpopulations involved in trans-synaptic tau transmission 
because our results suggest that other subpopulations are likely to be involved.  
Unexpectedly, CA1 cells contained pathogenic tau as well. CA1 cells in this group were 
contained tau because, in these mice, some of the cells in layer III of the medial entorhinal cortex 
had tTA in them (which allowed for the expression of tau in this pathway). In an ideal mouse 
model (one where there is no genetic variability between individuals), cells in layer III of this 
group would not have had tTA in them, and ultimately no cells would contain pathogenic tau in 
CA1. Due to limitations of the mouse line, the infection of cells in the CA1 region of the 




The known projection from layer III of the medial entorhinal cortex is to the CA1 region 
of the hippocampus. We examined the trans-synaptic spread of eGFPTau-P301L into 
postsynaptic hippocampal neurons following the virally-mediated transfection of LIII neurons of 
the MEC. Expression of eGFPTau-P301L depended on Cre-mediated recombination, which was 
largely restricted to layer III principal cells in the MEC. Layer III MEC neurons project 
exclusively to the CA1 region of the hippocampus. Therefore, we expected to observe trans-
synaptic spread of eGFPTau-P301L into CA1 neurons but not those of the DG or CA3. As 
expected, the CA1 cells of the hippocampus contained pathogenic tau. Upon further examination 
of the CA1 region, it was evident that interneurons contained pathogenic tau. Principal cells in 
CA1 appear to contain pathogenic tau in greater number than interneurons; however, about one 
third of cells that contain pathogenic tau in this region are interneurons. Keeping this in mind, 
since interneurons make up about 15% of neurons in CA1, this finding suggest that subsets of 
interneurons may be more susceptible to spread than CA1 principal cells based on probabilities. 
If everything was equal, we would have expected about 15% of tau containing neurons to be 
interneurons. Interneurons may be more susceptible to trans-synaptic spread of tau and this is 
contrary to previous research suggesting that principal cells are predominantly involved in 
tauopathy. No cells in the DG region or the CA3 region of the hippocampus contained trans-
synaptic pathogenic tau because, as expected, layer III of the medial entorhinal cortex does not 






Ventral CA1 has many known projections outside the hippocampal system, but this 
experiment was done to determine if interneurons can trans-synaptically spread tau to CA1 
principal cells. To do this we expressed eGFPTau-P301L in GABAergic neurons in hippocampal 
CA1 and assessed whether eGFPTau-P301L was trans-synaptically spread to postsynaptic CA1 
pyramidal neurons. The rationale for this experiment was that when virus is injected in ventral 
CA1, only interneurons will express GFP- tau because only interneurons have cre-recombinase 
in this group of mice. If principal cells in CA1 contained tau, this would suggest that 
interneurons are actively participating in the trans-synaptic spreading of tau. We did not know 
what to expect, except that only interneurons in vCA1 would be expressing GFP-tau in them.  
After a 3-month time point, interneurons and principal cells in CA1 both contained trans-
synaptic pathogenic tau. Additionally, interneurons and principal cells in DG and CA3 also 
contained pathogenic tau. The trans-synaptic spread of tau is more than likely due to diffusion 
from injection site into the DG and CA3 region of the hippocampus, not due to interneurons 
projecting backwards into these regions. Nevertheless, these results from the CA1 region of the 
hippocampus suggest that interneurons play an active role in the trans-synaptic spreading of tau. 




Because this was a discovery expedition, this study was more concerned with 
determining the trends of trans-synaptic tau transmission associated with hippocampal 
interneurons. Contrary to previous research, our results suggest that principal cells are not 
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exclusively involved in tauopathy and that interneurons are actively involved in trans- synaptic 
tau transmission within the hippocampus. This was determined by observing how tau progresses 
from three hippocampal pathways. This study has provided insight into the cell types that are 
affected by tauopathy, which is a hallmark of AD and other neurogenerative diseases. This 
understanding could lead to the discovery for new therapeutic targets for neurodegenerative 
diseases that are associated with tauopathy. More studies concerning the relationship between 
tauopathy and interneurons should progress for this discovery.  
Limitations, however, did exist in this study. All AAV injections were done manually 
through stereotactic surgery and injected into either the entorhinal cortex or the hippocampus to 
the best of our abilities. Although mice that received a missed injection were excluded from the 
data, minor variability in the injected area of interest will always exist for this type of 
methodology. Genetic uniqueness of transgenic animals in this study should also be considered. 
Although the transgenic mice from this study were received from professional services and were 
properly tested and controlled for, genetic uniqueness for each transgenic animal could have 
potentially affected the way trans-synaptic tau activity occurs in each hippocampal system as 
well as the cells affected and involved in tauopathy. The number of animals used in this study 
should also be considered. About 40 mice were used for this study. Because this was an 
exploratory study, some mice were excluded from the data because it was too early of a 
timepoint for cells to be affected by tau or too late of a timepoint and tau containing cells were 
dead; however, the majority of mice were excluded from this study because they received a 
missed injection. The data from this study are from the few successful injections. In the future, 
collecting data with more mice will be helpful to determine significance within the study.  
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Future studies should also determine the relationship between the role of sex differences 
and the prevalence of tau containing interneurons in hippocampal trans-synaptic tau activity. 
This study could have potentially given light on this subject, but there were not enough 
successful injections to make a worthy suggestion. Future studies should also determine other 
interneuron subpopulations affected by trans-synaptic tau transmission. The original plan of this 
study was to assess whether more subpopulations, not just calretinin interneurons, contained 
trans-synaptic pathogenic tau; however, there was not enough successful injections to examine 
other subtypes. Future studies should also determine how interneurons are affected as tau 
progresses from other areas of the entorhinal cortex and the hippocampus. This study only 
examined the pathways from layer II and layer III of the medial entorhinal cortex as well as 
ventral CA1 of the hippocampus. Examining pathways from the lateral entorhinal cortex as well 
as other regions of the hippocampus could potentially give insight as to how tau progresses and 






























Table 3: Animal Information for Thesis 
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